D-161[1] is a chemical known in research circles as a
triple reuptake inhibitor. Although this compound has lent support to the inclusion of
dopamine in the
monoamine hypothesis of depression, D-161 has not been tested in clinical trials.
References
^Dutta AK, Ghosh B, Biswas S, Reith ME (July 2008). "D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action". European Journal of Pharmacology. 589 (1–3): 73–9.
doi:
10.1016/j.ejphar.2008.05.008.
PMID18561912.